Table 4.

Best overall response

PatientsnORR (≥ PR), n (%)CBR (≥ MR), n (%)CR, n (%)VGPR, n (%)PR, n (%)*MR, n (%)SD, n (%)PD, n (%)
All patients4025 (63)32 (80)3 (8)9 (23)13 (33)7 (18)7 (18)1 (3)
Dose escalation patients1611 (69)13 (81)2 (13)4 (25)5 (31)2 (13)2 (13)1 (3)
RP2D patients2414 (58)19 (79)1 (4)5 (21)8 (33)5 (21)5 (21)
PI nonrefractory1916 (84)18 (95)2 (11)5 (26)9 (47)2 (11)1 (5)
PI refractory219 (43)14 (67)1 (5)4 (19)4 (19)5 (24)6 (29)1 (5)
PI and IMiD refractory198 (42)12 (63)4 (21)4 (21)4 (21)6 (32)1 (5)
  • The ORR and CBR were applied for all evaluable patients (n = 40). Two patients did not have sufficient disease measurements after 1 cycle of treatment and were therefore considered nonevaluable.

  • * Includes 1 unconfirmed PR.